In an independent cohort of 104 HCC patients treated with anti‐PD‐1 plus lenvatinib, 86 had available pre‐treatment PIVKA‐II measurements (Table S2, Supporting Information). Here, PDCD1 is linked to hepatocellular carcinoma.